Mitochondrial Dysfunction: Functional Medicine Assessment and Support Protocols
Mitochondrial dysfunction underlies fatigue, cognitive impairment, and accelerated ageing. Here's how functional medicine identifies it through OAT testing and organic acid biomarkers, and what the evidence supports for nutritional and botanical support.
Medical disclaimer: This article is for educational and informational purposes only. It is intended for healthcare practitioners and informed readers seeking to understand the current evidence base for mitochondrial health. Nothing here constitutes medical advice, diagnosis, or a personalised treatment recommendation. Individuals experiencing significant fatigue, cognitive impairment, or multi-system illness should be assessed by a qualified medical practitioner to exclude serious or primary causes before pursuing functional assessment.
Mitochondrial dysfunction has moved from the rare-disease genetics clinic into the mainstream of functional and integrative medicine. Once associated almost exclusively with devastating paediatric conditions such as Leigh syndrome and MELAS, the concept now sits at the intersection of fatigue medicine, metabolic health, and longevity science. The evidence base justifying this expansion is genuine — but it is also uneven, and it requires careful reading.
This article covers what mitochondria do at a biochemical level, how dysfunction arises and manifests clinically, what functional testing approaches can and cannot tell us, and where the nutritional and botanical support literature actually holds up.
What Mitochondria Do: ATP, the Electron Transport Chain, and Oxidative Phosphorylation
Every nucleated cell in the body contains mitochondria. Their central function is generating adenosine triphosphate (ATP) — the universal energy currency of cellular metabolism. The process unfolds across two interconnected pathways within the mitochondrion itself.
The tricarboxylic acid (TCA) cycle — also called the citric acid cycle or Krebs cycle — converts acetyl-CoA (derived from carbohydrates, fats, and amino acids) into carbon dioxide while reducing NAD+ to NADH and FAD to FADH2. These electron carriers are the fuel for the next stage. Key intermediates generated include citrate, isocitrate, succinate, fumarate, and malate — names that reappear in the organic acids testing section below.
Oxidative phosphorylation (OXPHOS) takes place across the electron transport chain (ETC): a series of protein complexes (I through IV) embedded in the inner mitochondrial membrane. Electrons from NADH and FADH2 pass through these complexes, driving protons across the membrane to create an electrochemical gradient. Complex V (ATP synthase) harvests the potential energy in this gradient to phosphorylate ADP to ATP. The final electron acceptor is molecular oxygen. When electron flow is impaired, electrons escape the chain and generate reactive oxygen species (ROS), which cause further mitochondrial damage — a self-amplifying cycle of oxidative stress.
Beyond ATP synthesis, mitochondria regulate apoptosis via cytochrome c release, buffer intracellular calcium, control cellular redox state, and generate biosynthetic precursors across multiple metabolic pathways. They are dynamic structures that continuously fuse and divide — a quality-control system that sequesters damaged components for degradation via mitophagy (the PINK1/Parkin pathway). When mitophagy is impaired, defective mitochondria accumulate, compounding energy deficits and oxidative burden.
Mitochondria carry their own genome (mtDNA) — a circular molecule encoding 13 ETC proteins. This DNA sits without histone protection, in close proximity to the ETC where ROS are generated, and has limited repair mechanisms. It accumulates somatic mutations with age, explaining why high-demand tissues — neurons, cardiomyocytes, skeletal muscle — are most vulnerable to mitochondrial compromise.
Causes of Mitochondrial Dysfunction
Secondary mitochondrial dysfunction — the domain functional medicine addresses — arises not from genetic mutations in ETC proteins, but from acquired factors that impair an otherwise structurally intact system:
Oxidative stress from chronic inflammation, poor antioxidant status, or ongoing toxic exposure directly damages ETC proteins and mtDNA, reducing electron transport efficiency and amplifying ROS generation in a self-reinforcing loop.
Nutrient deficiencies are among the most clinically actionable causes. The ETC and TCA cycle depend on a specific suite of micronutrient cofactors — CoQ10, carnitine, B vitamins (B1, B2, B3), magnesium, and alpha-lipoic acid. Deficiency in any of these creates functional bottlenecks even when mitochondrial structure is preserved.
Toxin exposure impairs mitochondrial function through several mechanisms. Heavy metals — mercury, arsenic, cadmium — directly inhibit ETC complexes. Organophosphate pesticides, alcohol, and certain pharmaceuticals (statins, some antiretrovirals, metformin at high doses) also interfere with CoQ10 synthesis or ETC function.
Ageing drives progressive mitochondrial deterioration: mtDNA mutations accumulate, mitophagy efficiency declines, and PGC-1alpha-driven biogenesis slows. By the sixth and seventh decades, measurable reductions in mitochondrial density and respiratory capacity are well-documented, contributing to the fatigue, muscle weakness, and cognitive changes of normal ageing.
Chronic infection and sustained immune activation shift cellular metabolism toward glycolysis at the expense of OXPHOS — a pattern observed in long COVID, ME/CFS, and other post-infectious fatigue syndromes.
Clinical Conditions Associated with Mitochondrial Dysfunction
No presentation is specific to secondary mitochondrial dysfunction, but several clinical patterns recur:
ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome): Research from the Hanson Laboratory at Cornell and groups at Stanford has demonstrated measurable bioenergetic impairment in ME/CFS cohorts — reduced ATP production, impaired Complex I activity, and abnormal lactate kinetics on two-day cardiopulmonary exercise testing. Post-exertional malaise, where symptoms worsen significantly 12–24 hours after physical or cognitive exertion, is the hallmark feature. The mitochondrial findings are real; causality versus consequence remains an open research question.
Fibromyalgia: Muscle biopsy studies have identified mitochondrial morphological abnormalities and reduced Complex I activity in some fibromyalgia cohorts. Fatigue and post-exertional worsening suggest shared bioenergetic mechanisms with ME/CFS, though central sensitisation is also central to fibromyalgia pathophysiology.
Metabolic syndrome and insulin resistance: Impaired mitochondrial biogenesis and reduced ETC capacity in skeletal muscle are well-documented in insulin-resistant states. Restoring metabolic flexibility — the ability to switch efficiently between fat and glucose oxidation — is a core therapeutic target.
Neurodegenerative conditions: Parkinson's disease, Alzheimer's disease, and ALS all show mitochondrial involvement. Complex I deficiency in substantia nigra neurons is among the most replicated findings in Parkinson's research. Whether this represents a primary driver or a downstream consequence of neuronal death remains debated.
Functional Medicine Testing: The Organic Acids Test (OAT)
The organic acids test measures small-molecule metabolic intermediates excreted in urine, providing a functional snapshot of cellular metabolic pathways. Several marker clusters are directly relevant to mitochondrial assessment.
TCA Cycle Intermediates
Elevated citrate, isocitrate, succinate, fumarate, and malate can indicate impaired downstream processing within the cycle — interpreted as functional bottlenecks at ETC complexes. Persistently elevated TCA intermediates may signal that substrate is accumulating behind a relative block in OXPHOS throughput. Elevated succinate in particular is associated with Complex II dysfunction in primary mitochondrial disease research, though interpretation in secondary dysfunction settings requires clinical context.
Fatty Acid Oxidation Markers
Adipate, suberate, and ethylmalonate are dicarboxylic acids that accumulate when long-chain fatty acid beta-oxidation is impaired — most commonly due to carnitine insufficiency, riboflavin deficiency, or specific acyl-CoA dehydrogenase impairments. Elevated adipate and suberate signal that fatty acids are being shunted to peroxisomal or omega-oxidation pathways rather than mitochondrial beta-oxidation, indicating the carnitine shuttle is not operating at full capacity.
Carnitine Shuttle Markers
Some OAT panels include markers that indirectly reflect carnitine adequacy. Dedicated plasma acylcarnitine profiling provides more specific carnitine shuttle information and is routinely used in paediatric metabolic screening. Where carnitine insufficiency is suspected from OAT findings, acylcarnitine fractionation is a logical follow-up.
Pyruvate, Lactate, and B12 Markers
An elevated lactate-to-pyruvate ratio suggests impaired pyruvate dehydrogenase function — dependent on thiamine (B1), lipoic acid, and CoA — indicating a functional block at the pyruvate-to-acetyl-CoA conversion step.
Elevated methylmalonic acid (MMA) reflects impaired methylmalonyl-CoA mutase, which requires adenosylcobalamin (a B12 coenzyme). Elevated urinary MMA is a sensitive marker of functional B12 deficiency even when serum B12 appears normal.
CoQ10 Serum Levels
CoQ10 serum levels are measured separately from the OAT — typically via HPLC from a fasting blood sample. Reference ranges vary between laboratories; levels below 0.5 µmol/L are generally considered deficient. Statin use, age, and certain chronic conditions reliably lower CoQ10 levels, and testing is most clinically meaningful in these contexts.
The OAT is genuinely useful for identifying nutrient cofactor deficiencies and metabolic bottlenecks. Its limitations are real: reference ranges vary between laboratories, single-point urine samples are subject to dietary and hydration variables, and mildly elevated intermediates require careful contextual interpretation. The test functions best as a hypothesis-generating tool rather than a standalone diagnostic.
Nutritional Support Protocols: What the Evidence Shows
CoQ10 — Ubiquinol vs Ubiquinone
CoQ10 is an essential lipophilic component of the ETC, shuttling electrons between Complexes I/II and Complex III. Endogenous synthesis declines with age and is suppressed by statins via HMG-CoA reductase inhibition.
The strongest clinical evidence is in statin-associated musculoskeletal symptoms, where multiple RCTs have shown improvements in muscle pain and exercise capacity at 100–300 mg/day. Evidence in heart failure and primary mitochondrial disease is also meaningful.
Ubiquinol — the reduced, electron-rich form — has superior oral bioavailability compared to ubiquinone (the oxidised form) at equivalent doses. Langsjoen and Langsjoen (2014) demonstrated that plasma CoQ10 levels achieved with ubiquinol were substantially higher than those achieved with equivalent ubiquinone doses in older adults with heart failure, suggesting the reduced form is preferable where absorption is a concern. Both forms are metabolically interconvertible in vivo; ubiquinol's advantage is primarily pharmacokinetic, particularly relevant at higher dosing ranges or in older patients with compromised absorption.
L-Carnitine and Acetyl-L-Carnitine
L-carnitine transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system, enabling beta-oxidation. Without adequate carnitine, fatty acid entry into mitochondria is impaired and cellular energy yield from fat metabolism is reduced.
Clinical RCT evidence supports L-carnitine at 2–3 g/day for fatigue and exercise capacity in cardiac failure and for some aspects of ME/CFS symptom burden. Secondary carnitine depletion occurs in renal failure, with valproate and some anticonvulsants, and in prolonged low-protein diets.
Acetyl-L-carnitine (ALCAR) carries acetyl groups across the mitochondrial membrane and additionally supports acetylcholine synthesis, making it the form of primary interest for cognitive and neurological applications. Evidence for ALCAR in mild cognitive impairment and peripheral neuropathy is modest but positive across several trials.
Riboflavin (B2), Niacinamide (B3/NAD+ Precursor), and Thiamine (B1)
Thiamine (B1) is an indispensable cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. Deficiency — occurring in alcohol dependence, malabsorptive conditions, and prolonged high-carbohydrate intake without adequate thiamine — causes pyruvate accumulation and lactic acidosis. Functional thiamine insufficiency has been proposed in ME/CFS and fibromyalgia; small trials using high-dose thiamine have shown symptom benefit in these populations, though the evidence remains preliminary.
Riboflavin (B2) is a flavoprotein component of both Complex I (as FMN) and Complex II (as FAD). It is well-established as treatment for riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency and is among the most consistently beneficial nutrients in migraine prevention — an effect that may involve its role in mitochondrial energy production in neural tissue.
Niacinamide (B3) and NAD+ precursors: NAD+ is the core electron carrier driving NADH production in the TCA cycle and beta-oxidation, feeding electrons to Complex I. NAD+ levels decline measurably with age. Precursors including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and niacinamide itself reliably raise blood NAD+ levels in human trials. Translation to measurable clinical outcomes in healthy ageing populations is less consistent, though improvements in metabolic parameters and some measures of muscle function have been reported.
Alpha-Lipoic Acid
Alpha-lipoic acid (ALA) is an endogenous mitochondrial cofactor serving as a prosthetic group for both pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. It is also a potent antioxidant capable of regenerating vitamins C and E and glutathione, and chelates certain transition metals.
RCTs at 300–600 mg/day show consistent benefit in diabetic peripheral neuropathy — improvements in nerve conduction velocity and symptom scores have been replicated across multiple trials, representing one of the more robust clinical evidence bases in the mitochondrial nutrient space. The mechanisms likely involve antioxidant, anti-inflammatory, and direct cofactor roles simultaneously.
Magnesium
Magnesium is a required cofactor for ATP synthase and for the hundreds of cellular ATPase enzymes that depend on Mg-ATP complexes. Deficiency — common in Western diets and exacerbated by chronic stress, alcohol use, and certain medications — impairs ATP utilisation broadly. Magnesium malate, which combines magnesium with malate (a TCA cycle intermediate), has been studied in fibromyalgia with modest but positive results for pain and fatigue. Evidence remains smaller in scale than for CoQ10 or ALA, and fibromyalgia pathophysiology is not reducible to mitochondrial dysfunction alone.
Botanical Support: PQQ and Shilajit
Pyrroloquinoline quinone (PQQ) is a redox-active compound found in small amounts in fermented foods and human breast milk. In mammalian research it has demonstrated the ability to stimulate mitochondrial biogenesis via activation of PGC-1alpha — the same transcriptional coactivator activated by aerobic exercise. Human trials are limited but suggest PQQ at 20 mg/day may improve mitochondrial-related outcomes including subjective energy and cognitive measures. The mechanistic rationale is solid; clinical translation in humans requires larger RCT confirmation.
Shilajit — a resinous exudate from high-altitude rock formations — contains fulvic acid and dibenzo-alpha-pyrones, which have been proposed to support CoQ10's activity in the ETC by maintaining it in a reduced, electron-donating state. A small RCT in healthy volunteers demonstrated that shilajit combined with CoQ10 produced greater improvements in mitochondrial bioenergetics markers than CoQ10 alone. The dibenzo-alpha-pyrone component is thought to interact directly with Complex II. The evidence base is early-stage, but the mechanistic hypothesis is specific enough to warrant monitoring as the trial literature matures.
A Note on Calibrating Clinical Expectations
The conditions most associated with mitochondrial dysfunction — ME/CFS, fibromyalgia, metabolic syndrome, neurodegenerative disease — are each complex, multifactorial, and not reducible to a single cellular mechanism. Mitochondrial support protocols should be understood as addressing one mechanistic layer among several, not as a complete therapeutic framework.
The clearest clinical benefit from nutritional mitochondrial support consistently appears in deficiency states: CoQ10 in statin users, thiamine in alcohol dependence, carnitine in renal failure. Extrapolating these findings to suggest that broad supplementation will restore energy in well-nourished individuals without documented deficiency is a different claim — one that requires its own evidence base, which is often mixed.
Aerobic exercise remains the single most robustly evidence-based stimulus for mitochondrial biogenesis. Endurance training activates PGC-1alpha, driving measurable increases in mitochondrial number and ETC Complex density within 6–8 weeks of regular training in previously sedentary individuals. This effect is more consistent and better evidenced than any supplement intervention for mitochondrial function in the general population.
Related Reading
The cellular ageing mechanisms that intersect most directly with mitochondrial biology — including the role of senescent cells in driving chronic inflammation and oxidative burden — are explored in depth in cellular senescence and senolytics. Practitioners working with comprehensive mineral and toxic metal assessment alongside organic acids will find the evidence base and interpretation framework for that modality in hair tissue mineral analysis (HTMA), including heavy metal burden that directly contributes to secondary ETC inhibition. For clinicians navigating the overlapping symptom clusters of fatigue, HPA dysregulation, and bioenergetic impairment, the evidence-based framing in adrenal fatigue: evidence vs myth provides a useful diagnostic counterpoint.
Naturopathic Science is an independent educational resource. No commercial affiliations or sponsored content influence the evidence presented here.